Curanex Pharmaceuticals Inc. (CURX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 14, 2026, by Curanex Pharmaceuticals Inc., a Nevada corporation. The report details a material modification to the rights of security holders regarding a reverse stock split. The company is listed on The Nasdaq Capital Market under the symbol "CURX" and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments rather than operational financial performance.
Material Changes
- Reverse Stock Split: The Board approved a 1-for-20 reverse stock split of the Company's common stock.
- Effective Date: The split became effective at 12:01 a.m. Pacific Time on August 20, 2026.
- Share Count Adjustment: Approximately 31,364,812 shares outstanding prior to the split were converted to approximately 1,568,241 shares post-split.
- Trading Status: The stock is expected to resume trading on Nasdaq on a reverse split-adjusted basis on August 20, 2026, under the existing symbol "CURX" but with a new CUSIP number.
- Fractional Shares: No fractional shares will be issued; entitlements are rounded up to the nearest whole share.
- Equity Awards: Proportionate adjustments were made to outstanding equity awards under the 2026 Equity Incentive Plan, including share counts and exercise/grant prices.
Outlook, Risks, and Management Commentary
Purpose: The primary objective of the reverse stock split is to regain compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) to maintain the company's listing on Nasdaq.
Process: VStock Transfer, LLC is acting as the exchange agent and will provide instructions to stockholders of record regarding the share exchange process.
Risks/Contingencies: The filing does not explicitly list new risks, though the necessity of the split implies prior non-compliance with Nasdaq listing standards. The total number of authorized common shares (475,000,000) and preferred shares (25,000,000) remains unchanged.
Key Facts for Investor Verification
- Verify the new CUSIP number for the stock once trading resumes on August 20, 2026.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-20 conversion.
- Review the adjusted exercise prices and share counts for any outstanding stock options or equity awards.
- Monitor the stock price post-split to ensure it meets the $1.00 minimum bid price requirement for continued Nasdaq listing.
- Check for any subsequent filings regarding the company's compliance status with Nasdaq following the effective date.